Kernal Biologics Presenting Results at the 9th Annual mRNA Health Conference
November 09, 2021 02:00 ET
|
Kernal Biologics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Kernal Biologics, Inc. (Kernal Bio) — an early-development-stage mRNA-technology company developing cancer therapeutics designed to improve...
INmune Bio, Inc. Announces Pricing of Initial Public Offering
January 15, 2019 15:00 ET
|
INmune Bio, Inc.
LA JOLLA, CA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s innate immune...
OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting
November 07, 2015 12:45 ET
|
OncoMed Pharmaceuticals, Inc.
NATIONAL HARBOR, Md. and REDWOOD CITY, Calif., Nov. 07, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and...